30 results about "ATRIAL RHYTHMS" patented technology

A cardiac rhythm management system includes techniques for computing an indicated pacing interval, AV delay, or other timing interval. In one embodiment, a variable indicated pacing interval is computed based at least in part on an underlying intrinsic heart rate. The indicated pacing interval is used to time the delivery of biventricular coordination therapy even when ventricular heart rates are irregular, such as in the presence of atrial fibrillation. In another embodiment, a variable filter indicated AV interval is computed based at least in part on an underlying intrinsic AV interval. The indicated AV interval is used to time the delivery of atrial tracking biventricular coordination therapy when atrial heart rhythms are not arrhythmic. Other indicated timing intervals may be similarly determined. The indicated pacing interval, AV delay, or other timing interval can also be used in combination with a sensor indicated rate indicator.

The invention belongs to the technical field of medical equipment, and particularly relates to an in-vitro defibrillator for distinguishing ventricular tachycardia and ventricular fibrillation automatically on the basis of a symbol sequence entropy of second derivative codes. In the in-vitro defibrillator, shockable rhythms are distinguished automatically to be the ventricular tachycardia or the ventricular fibrillation by calculating the symbol sequence entropy of second derivative codes of a signal, so that the appropriate defibrillation scheme is determined on the basis of the ventricular tachycardia or the ventricular fibrillation, wherein the scheme comprises the following steps of: preprocessing, namely filtering the collected electrocardiosignal; identifying if the electrocardiosignal is the shockable rhythms or not; calculating the symbol sequence entropy of the second derivative codes of the shockable rhythms; distinguishing the ventricular tachycardia / the ventricular fibrillation according to the symbol sequence entropy; and deciding the defibrillation scheme according to the ventricular tachycardia / the ventricular fibrillation. The in-vitro defibrillator can reduce the injury on mind and bodies of patients and improve the pertinence and success rate of defibrillation.

Implantable cardiac stimulator, with chamber stimulation unit connectable to left / right ventricular stimulation electrode to generate / deliver chamber stimulation pulses for stimulation of ventricle; ventricular sensing unit (VSU) to detect respective chamber contraction and deliver ventricular sensing signal when chamber contraction detected; optional atrial stimulation unit, connectable to atrial stimulation electrode to generate atrial stimulation pulses to stimulate atrium; atrial sensing unit, to detect atrial contraction, deliver atrial sensing signal indicating respective atrial event; tachycardia detection unit, connected to VSU to detect and categorize ventricular / supraventricular tachycardia; treatment control unit (TCU), triggers chamber stimulation unit to deliver antitachycardiac stimulation (ATP); analyzer unit, connected to atrial sensing unit and TCU. Analyzes atrial events from sensing unit before / during / after delivering antitachycardiac stimulation for atrial rhythm pattern during ventricular ATP by comparison atrial rhythm pattern immediately before ATP and to trigger TCU as function of ATP response signal representing comparison result for selection of the following antitachycardiac treatment.

The present invention relates to a method for the treatment or prevention of atrial fibrillation and / or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

An implantable pacing system with single, double and triple chamber pacing capabilities, provided individually or in concert on a conditional or continuous basis depending upon ongoing analyses of atrial rhythm status, atrioventricular conduction status and ventricular rate. A mode is selected to reduce the occurrence of any ventricular pacing in favor of intrinsic atrioventricular and ventricular conduction. If excessively long PR intervals are occurring too frequently or atrioventricular conduction is unreliable or absent, the implantable pulse generator is operated in a conditional triple chamber pacing mode that provides atrial-synchronous biventricular pacing in every cardiac cycle for a period of time as necessary to restore and maintain AV synchrony, while minimizing ventricular asynchrony otherwise associated with monochamber RV pacing as in conventional dual chamber pacing systems. Similarly, biventricular pacing is provided in every cardiac cycle when ventricular rates are undesirably slow during atrial fibrillation, where AV synchronization is excluded.

An implantable pacing system with single, double and triple chamber pacing capabilities, provided individually or in concert on a conditional or continuous basis depending upon ongoing analyses of atrial rhythm status, atrioventricular conduction status and ventricular rate. A mode is selected to reduce the occurrence of any ventricular pacing in favor of intrinsic atrioventricular and ventricular conduction. If excessively long PR intervals are occurring too frequently or atrioventricular conduction is unreliable or absent, the implantable pulse generator is operated in a conditional triple chamber pacing mode that provides atrial-synchronous biventricular pacing in every cardiac cycle for a period of time as necessary to restore and maintain AV synchrony, while minimizing ventricular asynchrony otherwise associated with monochamber RV pacing as in conventional dual chamber pacing systems. Similarly, biventricular pacing is provided in every cardiac cycle when ventricular rates are undesirably slow during atrial fibrillation, where AV synchronization is excluded.

A combination cardiac stimulator for CRT stimulation and CCM stimulation, which is connected to a rhythm evaluation unit which can either detect a sinus rhythm that is present, or classify an atrial arrhythmia, and which comprises an additional therapy selection unit, wherein the therapy selection unit selects the delivery of either CRT therapy or CCM therapy on the basis of the classification of the atrial rhythm such that CRT therapy is preferred in the case of sinus rhythm, and CCM therapy is delivered in the case of atrial arrhythmia.

An implantable pacing system with single, double and triple chamber pacing capabilities, provided individually or in concert on a conditional or continuous basis depending upon ongoing analyses of atrial rhythm status, atrioventricular conduction status and ventricular rate. A mode is selected to reduce the occurrence of any ventricular pacing in favor of intrinsic atrioventricular and ventricular conduction. If excessively long PR intervals are occurring too frequently or atrioventricular conduction is unreliable or absent, the implantable pulse generator is operated in a conditional triple chamber pacing mode that provides atrial-synchronous biventricular pacing in every cardiac cycle for a period of time as necessary to restore and maintain AV synchrony, while minimizing ventricular asynchrony otherwise associated with monochamber RV pacing as in conventional dual chamber pacing systems. Similarly, biventricular pacing is provided in every cardiac cycle when ventricular rates are undesirably slow during atrial fibrillation, where AV synchronization is excluded.

This application relates to an improved convolutional neural network and its training method for identifying heart rhythm types. ECG data known as atrial fibrillation or non-atrial fibrillation is used as a training database to train the neural network. The convolutional neural network consists of several convolutional neural networks. Layer and several pooling layers, a fully connected layer and a classifier layer, the loss function used is: using this loss function can make the convolutional neural network increase the penalty for false negatives during training, so as to achieve guaranteed accuracy Under the premise of reducing the missed detection rate and improving accuracy.

A wearable cardioverter defibrillator (“WCD”) system may output a loud sound after detecting and validating a shockable cardiac arrhythmia. In such embodiments, however, the WCD system might not sound a loud alarm before validating the arrhythmia thoroughly, i.e. for a longer time, thus giving the arrhythmia a further chance to self-terminate. The WCD system may thus detect more robustly the cardiac arrhythmias that do not self-terminate quickly. Such arrhythmias that self-terminate quickly may occur from likely harmless events occurring multiple times in the daily life of the patient, such as the patient becoming “winded” from climbing stairs. In embodiments the WCD system may notify the patient only discreetly, or even not at all. The lack of sounding such a loud alarm responsive to such events reduces the overall number of times in which the patient experiences unwanted attention by others, embarrassment, loss of privacy and dignity, and so on.

Health state trends for a consistent patient situation. Various noninvasive health monitors can be used to sense a patient's situation and health states, including disease progression, at those states. These noninvasive health monitors may also act passively and in a patient's normal course of life, which enhances many patient's desire to submit to monitoring, as well as increase consistency of use, as in many cases the patient does little or nothing to cause his or her health monitoring and health-trend determination. With health states determined for a consistent patient situation, more accurate and more robust health trends can be determined. In particular, parameters like cardiac rhythm, respiration rate or the spine curvature can be determined using a radar based motion sensing systemlocated in the vicinity of a patient's bed.

The invention discloses a device for discriminating malignant ventricular arrhythmia. After the sampling module discretely samples the continuous ECG signal; the amplitude-frequency characteristic extraction module extracts the amplitude-frequency characteristic of the signal and obtains a matrix; then the frequency band selection module Select the vector of the preset frequency band from the matrix to obtain a new matrix; then the feature extraction module will select the column vector of the preset number with the largest variance from the new matrix as the feature vector of the signal; the classification module will then The feature vector is input into a pre-trained classifier to obtain a classification result; finally, the discrimination module judges whether the electrocardiographic signal is a malignant ventricular rhythm according to the classification result. It can be seen that the device can select a preset number of vectors with the largest variance from the vectors of the preset frequency band as feature vectors, which effectively reduces the amount of calculation of the classifier and saves the time spent on discrimination. The present invention also provides a device for judging malignant ventricular rhythm, the function of which is corresponding to that of the above-mentioned device.